Pharmaceutical

Request for TOC Request for Sample
BUY NOW

Middle East and Africa Bladder Disorders Market – Industry Trends and Forecast to 2029

Pharmaceutical | Published Report | Sep 2022 | MEA | 350 Pages | No of Tables: 59 | No of Figures: 35

Report Description

Middle East and Africa Bladder Disorders Market, By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail) - Industry Trends and Forecast to 2029.

Get Exclusive Sample Copy of this Report Here

Middle East and Africa Bladder Disorders Market Analysis and Insights 

Bladder disorders are a group of disorders that can affect human life's daily activity. Some of the most common bladder disorders are cystitis- in which the bladder is infected and causes inflammation. Urinary incontinence- loss of bladder control, interstitial cystitis- bladder pain and frequent, urgent urination, and the overactive bladder- a condition in which the bladder squeezes urine. Bladder disorders can affect the quality of life and cause other health problems. Health changes and issues, including nervous system and lifestyle factors, can cause or contribute to UI in men and women.

Get Exclusive Sample Copy of this Report Here

Get Exclusive Sample Copy of this Report Here

The most common bladder disorders are overactive bladder and UI. These problems are associated with the nervous system. Nerves carry messages from the brain to the bladder, indicating muscles contract or release.

Middle East and Africa bladder disorders market are expected to grow in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2022 to 2029 and is expected to reach USD 519.60  million by 2029 from USD 327.73  million in 2021.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customisable 2019-2014)

Quantitative Units

Revenue in USD Million

Segments Covered

By Type (Cystitis, Urinary Incontinence, Overactive Bladder, Interstitial Cystitis, Bladder Cancer), Treatment Type (Surgery, Medication, Non-surgical), End User (Hospitals, Clinics, Ambulatory Surgery Centers, Others), Distribution Channel (Direct, Retail)

Countries Covered

South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, Rest of the Middle East and Africa

Market Players Covered

The major companies which are dealing in the market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.

Market Definition of Middle East and Africa Bladder Disorders Market

Bladder related disorders include cystitis - inflammation of the bladder, often from an infection, Urinary incontinence - loss of bladder control, Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time, Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination and bladder cancer.

Different tests are performed by the doctors to diagnose the bladder disorder that includes x-rays, urine tests, and a bladder wall examination by scope called cystoscope. The treatment of the disorder depends on the cause of the problem and the treatment includes medication, surgeries (in severe cases), and non-surgical procedures.

Anticholinergic medications are the first-line of pharmacotherapy in Overactive Bladder (OAB) syndrome. OAB is a clinical symptom characterized by urgency of desire to urine pass, which is difficult to defer, generally frequency to pass urine more than eight times per day are consider into OAB. Anticholinergic drugs inhibit the muscarinic receptors at the detrusor muscle that reduce the bladder contractility. To reduce the side effects, new medications with improved bladder selectivity and extended-release formulations are being developed. The majority of the more recent medications are equally effective at reducing the symptoms of an overactive bladder.

Middle East and Africa Bladder Disorders Market Dynamics

Drivers

  • STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

Bladder disorders are a number of bladder issues that can affect daily physical activities. The most common bladder disorders are cystitis, interstitial cystitis, overactive bladder, urinary incontinence, and bladder cancer. Most bladder issues are caused by a bacterial infection that enters the urinary tract.

Various strategic initiatives by the market players in terms of collaboration, acquisition, partnership, and others, allow them to increase their company's product portfolio, leading to market expansion and hence enhancing the product demand among customers, which ultimately provides the market players to earn maximum revenue.

  • GROWING GERIATRIC POPULATION

Aging is a strong risk factor that can associate with bladder-related disorders. Aging prompts neurologic, anatomic, and biochemical changes in bladder function, which can lead to the development of OAB. Overactive bladder is the most common problem among the geriatric population. Aging population is suffering from various bladder-associated problems and disorders due to which they are the predominant users of chronic health management services and solutions.

According to the noble study, the prevalence rate of overactive bladder is approximately 16.9 in women and men, around 16.0%, and the prevalence of OAB is growing with age. However, there are treatment guidelines that specify the preferred first-, second-, and third-line OAB therapy strategies. Bladder disorders are associated with Neurologic disorders such as dementia, and in this age group, OAB is very challenging for the senior population. Over the last few decades, the old age population has been drastically growing worldwide.

  • RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

Nowadays, various treatment options and innovative therapies are available for OAB and other bladder disorders. Many biopharmaceutical and pharmaceutical companies are investing in various unconventional therapies for bladder disorders, which are expected to launch during the forecast period.

  • COMBINATION OF DIFFERENT TARGET THERAPIES

Combination Therapies are much more effective than monotherapy, without additional side effects. Combination Therapies are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieve patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

  • SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

Chronic diseases are considered one of the major leading causes of death in developing countries worldwide. Therefore, the importance of healthcare management of chronic management is increased among public health practitioners.

Bladder disorder management now emphasizes assisting patients with various alternatives for self-care and a range of consultation services to educate patients about their illness and move forward. These therapies also assist patients in getting over emotional trauma and anxiety, which may act as a counter-protective mechanism.

Rising technical breakthroughs allow healthcare organizations to explore innovative services and solutions for managing chronic bladder disorders. Since they are not required to stay in the hospital for an extended period of time, they have also decreased costs and patient volume. Furthermore, lowering hospital visits and stays makes this development convenient for older adults. Taking into consideration the favorable aspects, many organizations and businesses are developing and implementing the most recent technologies in the management of chronic diseases to enhance patient outcomes.

  • RISING DISEASE MANAGEMENT PROGRAMS

People with bladder-related problems typically need more medical services, such as hospital stays, doctor visits, and prescription medications. Rise in the number of people living longer with many chronic problems coupled with increasing healthcare expenditures has encouraged better healthcare plans.

Disease management is one strategy that tries to improve care while lowering the expense of caring for the chronically ill. Programs for managing diseases aim to enhance the health of people with certain chronic disorders such as bladder disorders while lowering the demand for medical services and associated expenses for consequences that can be avoided, such as hospital stays and emergency visits. These programs also include information regarding chronic disease management services and solutions. These are becoming very popular owing to the rising prevalence of chronic diseases worldwide. Government and healthcare organizations have organized and implemented these chronic diseases with multiple disease management programs such as bladder cancer, interstitial cystitis, and overactive bladder management programs. Since disease management programs can significantly improve self-care practices and reduce hospital visits and staying periods to a more excellent extent, they receive more attention among people.

Restraints/Challenges

However, the difficulty in diagnosing the disease and the cost of the treatments and diagnostics are high due to the procedure of various checkpoints along with the high-tech technologies and modalities to perform the procedures. The cost of the procedure generally gets elevated because of the high cost of the advanced technological devices used in the treatment, which is expected to restrain the market growth.

This bladder disorders market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa bladder disorders market, contact Data Bridge Market Research for an Analyst Brief. Our team will help you make an informed market decision to achieve market growth.

Post COVID-19 Impact on Middle East and Africa Bladder Disorders Market

COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market

Recent Development

  • In March 2020, Astellas Pharma Inc. revealed that the U.S FDA approved Myrbetriq® (mirabegron extended-release tablets) for the treatment of NDO in pediatric patients aged three years and older who weigh 35 kg or more, and Myrbetriq® Granules (mirabegron for extended-release oral suspension) for the treatment of neurogenic detrusor over activity (NDO) in pediatric patients aged three years and older. This approval will increase the drug's global presence and elevate the company's revenue

Middle East and Africa Bladder Disorders Market Scope

Middle East and Africa bladder disorders market are segmented into type, treatment type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Type

On the basis of type, the Middle East and Africa bladder disorders market is segmented into cystitis, urinary incontinence, overactive bladder, interstitial cystitis, bladder cancer

Treatment type

  • Surgery
  • Medications
  • Others

On the basis of product, the Middle East and Africa bladder disorders market is segmented into surgery, medication, and others

End User

  • Hospital
  • Clinics
  • Ambulatory Surgery centers
  • Others

On the basis of end users, the Middle East and Africa bladder disorders market is segmented into hospitals, clinics, ambulatory surgery centers, and others

Distribution Channel

  • Direct
  • Retail

Get Exclusive Sample Copy of this Report Here

On the basis of distribution channel, the Middle East and Africa bladder disorders market is segmented into direct and retail

Middle East and Africa Bladder Disorders Market Regional Analysis/Insights

Middle East and Africa bladder disorders market is analyzed, and market size insights and trends are provided by country, type, treatment type, end user, and distribution channel, as referenced above.

Countries covered in this market are South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of the Middle East and Africa.

Saudi Arabia dominates the Middle East and Africa bladder disorders market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence of overactive bladder disorder in the region, and the growing geriatric population is boosting the market

The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of the Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Bladder Disorders Market Share Analysis

Middle East and Africa bladder disorders market competitive landscape provides details about the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the company’s focus on the Middle East and Africa bladder disorders market.

Some of the major players operating in the Middle East and Africa bladder disorders market are Medtronic, Laborie, Boston Scientific Corporation, Pfizer Inc., Astellas Pharma Inc., KYORIN Pharmaceutical Co., Ltd. (A subsidiary of KYORIN Holdings, Inc.), Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Axonics, Inc., Merck & Co., Inc., Viatris Inc., Gaylord Chemical Company, L.L.C., Coloplast Corp, AbbVie Inc., Sun Pharmaceutical Industries Ltd., Zydus Group, Swati Spentose, Urovant Sciences among others.

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, MEA  vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands' understanding of the market for additional countries (ask for the list of countries), clinical trial results in data, literature review, refurbished market, and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report


SKU-

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET END USER COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER'S FIVE FORCES

4.3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, PIPELINE ANALYSIS

5 MIDDLE EAST & AFRICA BLADDER DISORDER MARKET: REGULATIONS

5.1 THE U.S. REGULATORY FRAMEWORK FOR BLADDER DISOREDER MEDICATION

5.2 EUROPE REGULATORY FRAMEWORK FOR BLADDER DISORDER DRUGS

5.3 JAPAN REGULATORY GUIDANCE ON BLADDER DISORDER DRUGS

6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET OVERVIEW

6.1 DRIVERS

6.1.1 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS

6.1.2 GROWING GERIATRIC POPULATION

6.1.3 RISING R&D INVESTMENTS AND LAUNCH OF NOVEL THERAPIES IN UPCOMING YEARS

6.1.4 COMBINATION OF DIFFERENT TARGET THERAPIES

6.2 RESTRAINTS

6.2.1 HIGH COST ASSOCIATED WITH BLADDER DISORDER DIAGNOSTIC TREATMENT

6.2.2 PRODUCTS RECALLS FROM MARKET

6.3 OPPORTUNITIES

6.3.1 SURGE IN NOVEL TECHNOLOGICAL ADVANCEMENTS

6.3.2 RISING DISEASE MANAGEMENT PROGRAMS

6.4 CHALLENGES

6.4.1 LACK OF AWARENESS ABOUT BLADDER DISORDERS RELATED PROBLEMS

6.4.2 PATENT EXPIRY OF DRUGS

7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TYPE

7.1 OVERVIEW

7.2 OVERACTIVE BLADDER

7.3 URINARY INCONTINENCE

7.4 CYSTITIS

7.5 INTERSTITIAL CYSTITIS

7.6 BLADDER CANCER

7.7 OTHERS

8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE

8.1 OVERVIEW

8.2 MEDICATION

8.2.1 TOLTERODINE

8.2.2 MIRABEGRON

8.2.3 FESOTERODINE

8.2.4 OXYBUTYNIN

8.2.5 SOLIFENACIN

8.2.6 DARIFENACIN

8.2.7 TROSPIUM

8.2.8 OTHERS

8.3 SURGERY

8.3.1 SURGERY TO INCREASE BLADDER CAPACITY

8.3.2 BLADDER REMOVAL

8.3.3 OTHERS

8.4 OTHERS

9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 DIRECT

9.3 RETAIL

10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY END USER

10.1 OVERVIEW

10.2 HOSPITALS

10.3 CLINICS

10.4 AMBULATORY SURGICAL CENTERS

10.5 OTHERS

11 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY GEOGRAPHY

11.1 MIDDLE EAST AND AFRICA

11.1.1 SAUDI ARABIA

11.1.2 SOUTH AFRICA

11.1.3 UAE

11.1.4 EGYPT

11.1.5 ISRAEL

11.1.6 REST OF MIDDLE EAST AND AFRICA

12 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY LANDSCAPE

12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

13 SWOT ANALYSIS

14 COMPANY PROFILE

14.1 MERCK AND CO. INC. (2021)

14.1.1 COMPANY SNAPSHOT

14.1.2 REVENUE ANALYSIS

14.1.3 COMPANY SHARE ANALYSIS

14.1.4 PRODUCT PORTFOLIO

14.1.5 RECENT DEVELOPMENT

14.2 ASTELLAS PHARMA INC. (2021)

14.2.1 COMPANY SNAPSHOT

14.2.2 REVENUE ANALYSIS

14.2.3 COMPANY SHARE ANALYSIS

14.2.4 PRODUCT PORTFOLIO

14.2.5 RECENT DEVELOPMENTS

14.3 BRISTOL-MYERS SQUIBB COMPANY (2021)

14.3.1 COMPANY SNAPSHOT

14.3.2 REVENUE ANALYSIS

14.3.3 COMPANY SHARE ANALYSIS

14.3.4 PRODUCT PORTFOLIO

14.3.5 RECENT DEVELOPMENT

14.4 BOSTON SCIENTIFIC CORPORATION (2021)

14.4.1 COMPANY SNAPSHOT

14.4.2 REVENUE ANALYSIS

14.4.3 COMPANY SHARE ANALYSIS

14.4.4 PRODUCT PORTFOLIO

14.4.5 RECENT DEVELOPMENT

14.5 VIATRIS INC. (2021)

14.5.1 COMPANY SNAPSHOT

14.5.2 REVENUE ANALYSIS

14.5.3 COMPANY SHARE ANALYSIS

14.5.4 PRODUCT PORTFOLIO

14.5.5 RECENT DEVELOPMENT

14.6 ABBVIE (2021)

14.6.1 COMPANY SNAPSHOT

14.6.2 REVENUE ANALYSIS

14.6.3 PRODUCT PORTFOLIO

14.6.4 RECENT DEVELOPMENT

14.7 AXONICS, INC. (2021)

14.7.1 COMPANY SNAPSHOT

14.7.2 REVENUE ANALYSIS

14.7.3 PRODUCT PORTFOLIO

14.7.4 RECENT DEVELOPMENT

14.8 BLUE WIND MEDICAL (2021)

14.8.1 COMPANY SNAPSHOT

14.8.2 PRODUCT PORTFOLIO

14.8.3 RECENT DEVELOPMENT

14.9 COLOPLAST CORP. (2021)

14.9.1 COMPANY SNAPSHOT

14.9.2 REVENUE ANALYSIS

14.9.3 PRODUCT PORTFOLIO

14.1 GAYLORD CHEMICAL COMPANY, LLC (2021)

14.10.1 COMPANY SNAPSHOT

14.10.2 PRODUCT PORTFOLIO

14.10.3 RECENT DEVELOPMENT

14.11 JOHNSON & JOHNSON SERVICES, INC. (2021)

14.11.1 COMPANY SNAPSHOT

14.11.2 REVENUE ANALYSIS

14.11.3 PRODUCT PORTFOLIO

14.11.4 RECENT DEVELOPMENT

14.12 KYORIN PHARMACEUTICAL CO., LTD. (A SUBSIDIARY OF KYORIN HOLDINGS, INC.) (2021)

14.12.1 COMPANY SNAPSHOT

14.12.2 PRODUCT PORTFOLIO

14.12.3 RECENT DEVELOPMENTS

14.13 LABORIE (2021)

14.13.1 COMPANY SNAPSHOT

14.13.2 PRODUCT PORTFOLIO

14.13.3 RECENT DEVELOPMENT

14.14 MEDTRONIC (2021)

14.14.1 COMPANY SNAPSHOT

14.14.2 REVENUE ANALYSIS

14.14.3 PRODUCT PORTFOLIO

14.14.4 RECENT DEVELOPMENTS

14.15 PFIZER INC. (2021)

14.15.1 COMPANY SNAPSHOT

14.15.2 REVENUE ANALYSIS

14.15.3 PRODUCT PORTFOLIO

14.15.4 RECENT DEVELOPMENTS

14.16 VALENCIA TECHNOLOGIES (2021)

14.16.1 COMPANY SNAPSHOT

14.16.2 PRODUCT PORTFOLIO

14.16.3 RECENT DEVELOPMENT

14.17 SUN PHAMACEUTICAL INDUSTRIES LTD. (2021)

14.17.1 COMPANY SNAPSHOT

14.17.2 REVENUE ANALYSIS

14.17.3 PRODUCT PORTFOLIO

14.17.4 RECENT DEVELOPMENT

14.18 SWATI SPENTOSE (2021)

14.18.1 COMPANY SNAPSHOT

14.18.2 PRODUCT PORTFOLIO

14.18.3 RECENT DEVELOPMENT

14.19 UROVANT SCIENCES (2021)

14.19.1 COMPANY SNAPSHOT

14.19.2 PRODUCT PORTFOLIO

14.19.3 RECENT DEVELOPMENT

14.2 ZYDUS GROUP (2021)

14.20.1 COMPANY SNAPSHOT

14.20.2 PRODUCT PORTFOLIO

14.20.3 RECENT DEVELOPMENT

15 QUESTIONNAIRE

16 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA OVERACTIVE BLADDER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA URINARY INCONTINENCE IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA INTERSTITIAL CYSTITIS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA BLADDER CANCER IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA MEDICATION IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA DIRECT IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA RETAIL IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA HOSPITALS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA CLINICS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA OTHERS IN BLADDER DISORDERS MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 29 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 30 SAUDI ARABIA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 31 SAUDI ARABIA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 32 SAUDI ARABIA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 33 SAUDI ARABIA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 SAUDI ARABIA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 35 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 36 SOUTH AFRICA BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 37 SOUTH AFRICA MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 38 SOUTH AFRICA SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 39 SOUTH AFRICA BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 40 SOUTH AFRICA BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 41 UAE BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 42 UAE BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 43 UAE MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 44 UAE SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 45 UAE BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 46 UAE BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 47 EGYPT BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 EGYPT BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 49 EGYPT MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 50 EGYPT SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 51 EGYPT BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 52 EGYPT BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 53 ISRAEL BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 54 ISRAEL BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 55 ISRAEL MEDICATIONS IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 56 ISRAEL SURGERY IN BLADDER DISORDERS MARKET, BY TREATMENT TYPE, 2020-2029 (USD MILLION)

TABLE 57 ISRAEL BLADDER DISORDERS MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 58 ISRAEL BLADDER DISORDERS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 59 REST OF MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BLADDER DISORDER MARKET

FIGURE 14 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2021

FIGURE 15 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021

FIGURE 19 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 23 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2021

FIGURE 27 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 31 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 32 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

View Infographics

FIGURE 1 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: SEGMENTATION

FIGURE 11 RISING EPIDEMIC AND PANDEMIC OUTBREAK AND INCREASING PREVALENCE OF BLADDER DISORDERS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 OVERACTIVE BLADDER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA BLADDER DISORDER MARKET

FIGURE 14 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2021

FIGURE 15 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2021

FIGURE 19 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY TREATMENT TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 23 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2021

FIGURE 27 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: BY END USER, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: SNAPSHOT (2021)

FIGURE 31 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021)

FIGURE 32 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2022 & 2029)

FIGURE 33 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY COUNTRY (2021 & 2029)

FIGURE 34 MIDDLE EAST AND AFRICA BLADDER DISORDERS MARKET: BY TYPE (2022-2029)

FIGURE 35 MIDDLE EAST & AFRICA BLADDER DISORDERS MARKET: COMPANY SHARE 2021 (%)

CHOOSE LICENCE TYPE
  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19